Document Detail


Postprandial changes in plasma acylcarnitine concentrations as markers of fatty acid flux in overweight and obesity.
MedLine Citation:
PMID:  21820684     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
This study determined whether reductions in postprandial plasma nonesterified fatty acid (FFA) flux would lead to reductions in plasma acylcarnitine (AC) concentrations. Plasma AC was measured by liquid chromatography with tandem mass spectrometry in the fasting state and over 6 hours after a high-fat (50% energy) meal was fed to 16 overweight and obese subjects with a wide range of insulin sensitivities. Body composition was measured by dual-energy x-ray absorptiometry; insulin sensitivity by insulin-modified, frequently sampled intravenous glucose tolerance test; substrate oxidation by indirect calorimetry; blood metabolite and hormone concentrations biochemically; and fatty acid flux by using stable isotope tracers. Lean body mass and fasting fat oxidation correlated positively (r > 0.522, P < .05), whereas glucose oxidation correlated negatively (r < -0.551, P < .04), with fasting AC. Postprandially, plasma glucose, insulin, and triglyceride concentrations increased; and FFA concentrations decreased significantly. The responses of plasma AC species depended on chain length and saturation, with C14:0, C16:0, and C18:0 remaining unchanged, and unsaturated species (eg, C14:1, C14:2) falling significantly (21%-46%, P < .03). Postmeal nadir AC concentrations were positively associated with lean body mass, postprandial fatty acid flux, and FFA concentrations (r > 0.515, P < .05). By contrast, nadir AC correlated negatively with insulin sensitivity and spillover of meal-derived fatty acids (r < -0.528, P < .04). Conditions that impact fatty acid flux contribute to the control of postprandial plasma AC concentrations. These data underscore the need for a better understanding of postprandial fatty acid oxidation and dietary fat delivery in the setting of adipose insulin resistance to determine how postprandial lipemia contributes to chronic disease risk.
Authors:
Maria A Ramos-Roman; Lawrence Sweetman; Maressa J Valdez; Elizabeth J Parks
Related Documents :
1173274 - Distribution of fatty acids during germination of cottonseeds.
15354584 - Influence of manufacturing conditions on the conjugated linoleic acid content and the i...
22062754 - Water-soluble precursors of beef flavour. part ii: effect of post-mortem conditioning.
1387324 - Gestational hyperlipidemia in the rat is characterized by accumulation of n - 6 and n -...
3088674 - Prostaglandin synthesis by enterocyte microsomes of rabbit small intestine.
21895464 - Fatty acids of rhodobryum ontariense (bryaceae).
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, N.I.H., Extramural     Date:  2011-08-05
Journal Detail:
Title:  Metabolism: clinical and experimental     Volume:  61     ISSN:  1532-8600     ISO Abbreviation:  Metab. Clin. Exp.     Publication Date:  2012 Feb 
Date Detail:
Created Date:  2012-01-24     Completed Date:  2012-03-20     Revised Date:  2013-06-28    
Medline Journal Info:
Nlm Unique ID:  0375267     Medline TA:  Metabolism     Country:  United States    
Other Details:
Languages:  eng     Pagination:  202-12     Citation Subset:  IM    
Copyright Information:
Copyright © 2012 Elsevier Inc. All rights reserved.
Affiliation:
Division of Endocrinology and Metabolism, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390-8857, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Biological Markers / analysis,  blood
Biological Transport
Body Composition / physiology
Carnitine / analogs & derivatives*,  analysis,  blood
Fatty Acids / blood,  metabolism*
Female
Humans
Lipid Metabolism / physiology
Male
Middle Aged
Obesity / blood,  metabolism*
Osmolar Concentration
Overweight / blood,  metabolism*
Postprandial Period* / physiology
Young Adult
Grant Support
ID/Acronym/Agency:
5PL1DK081183-04/DK/NIDDK NIH HHS; 5RL1DK081187-04/DK/NIDDK NIH HHS; KL2 RR024983-01/RR/NCRR NIH HHS; KL2 RR024983-02/RR/NCRR NIH HHS; KL2 RR024983-03/RR/NCRR NIH HHS; P20 RR020691-01/RR/NCRR NIH HHS; P20 RR020691-02/RR/NCRR NIH HHS; P20 RR020691-03/RR/NCRR NIH HHS; PL1 DK081183-01/DK/NIDDK NIH HHS; PL1 DK081183-02/DK/NIDDK NIH HHS; PL1 DK081183-02S1/DK/NIDDK NIH HHS; PL1 DK081183-03/DK/NIDDK NIH HHS; PL1 DK081183-04/DK/NIDDK NIH HHS; PL1 DK081183-04S1/DK/NIDDK NIH HHS; PL1 DK081183-05/DK/NIDDK NIH HHS; RL1 DK081187/DK/NIDDK NIH HHS; RL1 DK081187-01/DK/NIDDK NIH HHS; RL1 DK081187-02/DK/NIDDK NIH HHS; RL1 DK081187-03/DK/NIDDK NIH HHS; RL1 DK081187-04/DK/NIDDK NIH HHS; RL1 DK081187-05/DK/NIDDK NIH HHS; TL1 RR024984-01/RR/NCRR NIH HHS; TL1 RR024984-02/RR/NCRR NIH HHS; TL1 RR024984-03/RR/NCRR NIH HHS; UL1 DE019584-02/DE/NIDCR NIH HHS; UL1 DE019584-03/DE/NIDCR NIH HHS; UL1 DE019584-04/DE/NIDCR NIH HHS; UL1 DE019584-05/DE/NIDCR NIH HHS; UL1 RR024923-01/RR/NCRR NIH HHS; UL1 RR024982-01/RR/NCRR NIH HHS; UL1 RR024982-02/RR/NCRR NIH HHS; UL1 RR024982-03/RR/NCRR NIH HHS; UL1-RR02498/RR/NCRR NIH HHS; UL1DE019584-04/DE/NIDCR NIH HHS
Chemical
Reg. No./Substance:
0/Biological Markers; 0/Fatty Acids; 0/acylcarnitine; 541-15-1/Carnitine
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  P/Ca in coral skeleton as a geochemical proxy for seawater phosphorus variation in Daya Bay, norther...
Next Document:  Prophylactic treatment with telmisartan induces tissue-specific gene modulation favoring normal gluc...